Durable responses with intratumoral electroportation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890

Melinda L. Telli1, Irene Wapnir1, Blanca Devitt2, Katherine Cuff3, Hatem Soliman1, Savaela Visayak,4 David A. Cantor5, Christopher Twitty6, Sorey Xie7, Ying Lu8, Donna Baranowang,9 Bridget O’Keefe10, Sandra Aung11, Rohit Joshi12

1Stanford University School of Medicine, Stanford, CA, USA; 2Beaumont Hospital, Royal Oak, MI, USA; 3Academic Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; 4Ruijin Hospital, Shanghai, China; 5University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 6The University of Chicago, Chicago, IL, USA; 7Adelaide Oncology and Hemato-oncology, Adelaide, SA, Australia; 8Brigham and Women’s Hospital, Boston, MA, USA; 9University of Minnesota, Minneapolis, MN, USA; 10Moffit Cancer Center, Tampa, FL, USA; 11Adelaide University, Adelaide, SA, Australia; 12University of Chicago, Chicago, IL, USA

Results

PD-L1 expression of PD-L1 in patients with melanoma and TNBC, without the systemic toxicity that limited therapeutic use of IL-12 historically.3

Mechanism of Action of TAVO-EP

The combination of plasmid IL-12 (TAVO-EP) and pembrolizumab in pretreated patients with metastatic TNBC resulted in durable RECIST v1.1 responses (median 16.6 months).

Cohort 1 update from KEYNOTE-890

Melinda L. Telli1, Irene Wapnir1, Blanca Devitt2, Katherine Cuff3, Hatem Soliman1, Savaela Visayak,4 David A. Cantor5, Christopher Twitty6, Sorey Xie7, Ying Lu8, Donna Baranowang,9 Bridget O’Keefe10, Sandra Aung11, Rohit Joshi12

1Stanford University School of Medicine, Stanford, CA, USA; 2Beaumont Hospital, Royal Oak, MI, USA; 3Academic Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; 4Ruijin Hospital, Shanghai, China; 5University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 6The University of Chicago, Chicago, IL, USA; 7Adelaide Oncology and Hemato-oncology, Adelaide, SA, Australia; 8Brigham and Women’s Hospital, Boston, MA, USA; 9University of Minnesota, Minneapolis, MN, USA; 10Moffit Cancer Center, Tampa, FL, USA; 11Adelaide University, Adelaide, SA, Australia; 12University of Chicago, Chicago, IL, USA

Results

PD-L1 expression of PD-L1 in patients with melanoma and TNBC, without the systemic toxicity that limited therapeutic use of IL-12 historically.3

Mechanism of Action of TAVO-EP

The combination of plasmid IL-12 (TAVO-EP) and pembrolizumab in pretreated patients with metastatic TNBC resulted in durable RECIST v1.1 responses (median 16.6 months).